Skip to content

Find out the Winner of the 5th Annual Shauna M. Sorrells Grant Program

Proven Results

G2G has worked to secure millions of dollars for our clients, led advocacy campaigns, written policy proposals and position statements, organized Capitol Hill Fly-Ins and Statehouse Days to meet with public officials and staff, and planned media events. Below are a few case studies demonstrating the breadth and depth of our work and how we turn challenges into opportunities for our clients.

Explore by Industry

All
  • All
  • Defense
  • Education
  • Health
  • Nonprofit
  • Ohio Case Studies
G2G Blog Banners (3)

Summary of the Government Biotechnology Innovation Summit

On September 27-28, G2G attended the Inaugural Government Biotechnology Innovation Summit in National Harbor, MD. The forum was centered on highlighting the ongoing whole of government approach towards bolstering the bioeconomy, biosecurity and national security, and opportunities for industry to engage with the government to meet these goals.

national-cancer-institute-fi3zHLxWrYw-unsplash

Rapid Vaccine Development Technology

Goal: Secure funds for rapid vaccine development technology

dj-johnson-4JHy5rxsF5g-unsplash

Obtaining Cleveland Funding

Goal: Establish a public private partnership and secure funding to build proven technology for drone tracking and management in Ohio

matthew-bornhorst-LbMrK7wfm_o-unsplash

Organizing Advocacy Campaigns

Goal: Build relationships for and raise the profile of a new statewide nonprofit for healthy food access in order access state funding to expand programming

5e55a145f68d1440adc6e255_shutterstock_1270562848 copy

Managing a National Association and Passing Legislation

Goal: Establish Washington, D.C. presence and influence for national coalition with members in 36 states.

5e5ab2323c3e0f2a1becf254_Non Profit

Raising Awareness and Changing Policy for National Nonprofit

Goal: Educate on the national organization, how common rare cancers are, the gaps in current therapeutic options and R&D system for rare cancer patients, and the need for policy changes.